JP2005521643A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005521643A5 JP2005521643A5 JP2003545797A JP2003545797A JP2005521643A5 JP 2005521643 A5 JP2005521643 A5 JP 2005521643A5 JP 2003545797 A JP2003545797 A JP 2003545797A JP 2003545797 A JP2003545797 A JP 2003545797A JP 2005521643 A5 JP2005521643 A5 JP 2005521643A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- angptl3
- antibody
- medicament
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 18
- 102000004965 antibodies Human genes 0.000 claims 10
- 108090001123 antibodies Proteins 0.000 claims 10
- 101710043744 ANGPTL3 Proteins 0.000 claims 7
- 230000002757 inflammatory Effects 0.000 claims 6
- 201000009673 liver disease Diseases 0.000 claims 6
- 208000006454 Hepatitis Diseases 0.000 claims 3
- 210000004185 Liver Anatomy 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000003042 antagnostic Effects 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 230000027455 binding Effects 0.000 claims 3
- 102000006495 integrins Human genes 0.000 claims 3
- 108010044426 integrins Proteins 0.000 claims 3
- 230000035693 Fab Effects 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 201000004044 liver cirrhosis Diseases 0.000 claims 2
- 208000002353 Alcoholic Hepatitis Diseases 0.000 claims 1
- 208000010002 Alcoholic Liver Cirrhosis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010008909 Chronic hepatitis Diseases 0.000 claims 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 229940012952 Fibrinogen Drugs 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000005252 Hepatitis A Diseases 0.000 claims 1
- 208000002672 Hepatitis B Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000005331 Hepatitis D Diseases 0.000 claims 1
- 206010019773 Hepatitis G Diseases 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 102000018358 Immunoglobulins Human genes 0.000 claims 1
- 108060003951 Immunoglobulins Proteins 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 206010053219 Non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 230000010595 endothelial cell migration Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 201000010284 hepatitis E Diseases 0.000 claims 1
- 230000000302 ischemic Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 229920000023 polynucleotide Polymers 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000002588 toxic Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
Claims (17)
- Angptl3のアンタゴニストを有効成分として含む、炎症性肝疾患を治療又は予防するための医薬。
- 炎症性肝疾患がAngptl3の発現亢進を特徴とする、請求項1に記載の医薬。
- 炎症性肝疾患が肝臓への感染、自己免疫過程、又は化学的損傷に関する、請求項1に記載の医薬。
- 炎症性肝疾患が、肝硬変、肝線維症、肝炎、ウイルス性肝炎A、B、C、D、E又はG、毒代謝性肝障害、脂肪肝、肝臓の虚血性再環流障害、又は敗血症を含む、請求項1ないし3の何れか一に記載の医薬。
- 肝硬変が、アルコール性肝硬変又は原発性胆管硬変である、請求項4に記載の医薬。
- 肝炎が、慢性肝炎、自己免疫性肝炎、アルコール性肝炎又は非アルコール性脂肪肝炎である、請求項4に記載の医薬。
- アンタゴニストが、抗Angptl3抗体、抗αvβ3インテグリン抗体、又はイムノアドヘシンを含む、請求項1に記載の医薬。
- 抗Angptl3抗体又は抗αvβ3インテグリン抗体が、モノクローナル抗体、抗原結合抗体断片、キメラ抗体、ヒト化抗体、ヒト抗体、又は一本鎖抗体を含む、請求項7に記載の医薬。
- 抗体断片が、Fab、Fab’、F(ab)’ 2 、又はFv断片を含む、請求項8に記載の医薬。
- イムノアドヘシンが、イムノグロブリン配列に融合したαvβ3インテグリンのリガンド結合領域を含む、請求項7に記載の医薬。
- 予防が炎症性肝疾患の進行を予防することを含む、請求項1ないし10の何れか一に記載の医薬。
- Angptl3が配列番号:2に少なくとも80%のアミノ酸同一性を有するアミノ酸配列を含み、内皮細胞の移動を誘導する、請求項1ないし10の何れか一に記載の医薬。
- Angptl3がフィブリノゲンドメインを含む、請求項12に記載の医薬。
- Angptl3が配列番号:2のアミノ酸領域281−293、415−430、又は442−460の一以上を含む、請求項12又は13に記載の医薬。
- Angptl3が配列番号:2のアミノ酸配列を含む、請求項12ないし14の何れか一に記載の医薬。
- Angptl3が配列番号:1に記載の核酸配列を含むポリヌクレオチドにコードされる、請求項12ないし15の何れか一に記載の医薬。
- (a)容器;
(b)Angptl3のアンタゴニストを有効成分として含む医薬;と
(c)炎症性肝疾患の治療のための医薬の使用についての指示書、
とを含んでなるキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33242901P | 2001-11-16 | 2001-11-16 | |
US60/332,429 | 2001-11-16 | ||
PCT/US2002/036865 WO2003044172A2 (en) | 2001-11-16 | 2002-11-13 | Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009259497A Division JP2010100624A (ja) | 2001-11-16 | 2009-11-13 | アンジオポエチン様タンパク質3Angptl3含有組成物とその使用方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005521643A JP2005521643A (ja) | 2005-07-21 |
JP2005521643A5 true JP2005521643A5 (ja) | 2006-04-06 |
JP5105696B2 JP5105696B2 (ja) | 2012-12-26 |
Family
ID=23298191
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003545797A Expired - Fee Related JP5105696B2 (ja) | 2001-11-16 | 2002-11-13 | アンジオポエチン様タンパク質3Angptl3含有組成物とその使用方法 |
JP2009259497A Pending JP2010100624A (ja) | 2001-11-16 | 2009-11-13 | アンジオポエチン様タンパク質3Angptl3含有組成物とその使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009259497A Pending JP2010100624A (ja) | 2001-11-16 | 2009-11-13 | アンジオポエチン様タンパク質3Angptl3含有組成物とその使用方法 |
Country Status (14)
Country | Link |
---|---|
US (3) | US7267819B2 (ja) |
EP (1) | EP1451578B1 (ja) |
JP (2) | JP5105696B2 (ja) |
KR (2) | KR101012904B1 (ja) |
CN (2) | CN1615440A (ja) |
AU (1) | AU2002348286B2 (ja) |
CA (1) | CA2464542C (ja) |
ES (1) | ES2429034T3 (ja) |
IL (2) | IL161542A0 (ja) |
MX (1) | MXPA04004609A (ja) |
NO (1) | NO336021B1 (ja) |
NZ (1) | NZ532852A (ja) |
WO (1) | WO2003044172A2 (ja) |
ZA (1) | ZA200403070B (ja) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
CN1615440A (zh) | 2001-11-16 | 2005-05-11 | 杰南技术公司 | 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法 |
AU2004266043B2 (en) * | 2003-08-21 | 2007-09-20 | Duchesnay Inc. | Micronutrient supplement |
EP1771474B1 (en) | 2004-07-20 | 2010-01-27 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
AU2005269758B2 (en) | 2004-07-20 | 2011-11-03 | Genentech, Inc. | Compositions and methods of using angiopoietin-like 4 protein |
US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
WO2007038407A2 (en) | 2005-09-23 | 2007-04-05 | The Regents Of The University Of California | Compositions and methods for treating nervous system disorders |
KR101503937B1 (ko) * | 2006-12-08 | 2015-03-18 | 렉시컨 파마슈티컬스 인코퍼레이티드 | Angptl3 에 대한 단일클론 항체 |
EP2265638A1 (en) * | 2008-04-14 | 2010-12-29 | Hadasit Medical Research Services And Development Ltd. | Stable cell binding chimeric peptides |
CN101852805B (zh) * | 2009-03-31 | 2015-04-01 | 浙江大学 | Angptl3作为卵巢癌的诊断标记物的用途 |
MA33423B1 (fr) | 2009-07-14 | 2012-07-03 | Scripps Research Inst | Différentiation de cellules souches mésenchymateuses |
CN106146591B (zh) * | 2010-01-08 | 2020-07-31 | Ionis制药公司 | 血管生成素样3表达的调节 |
AU2015200969A1 (en) * | 2010-01-08 | 2015-03-19 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
CN102687027B (zh) * | 2010-02-02 | 2016-05-25 | 阿利桑那卅评议会 | 用于测序聚合物的受控的隧道间隙设备 |
EP2668499A4 (en) * | 2011-01-29 | 2015-05-27 | Astute Medical Inc | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE |
JO3412B1 (ar) * | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
US9403877B2 (en) | 2012-01-24 | 2016-08-02 | Inter-K Pty Limited | Peptide agents for cancer therapy |
US9301971B2 (en) | 2013-03-08 | 2016-04-05 | Novartis Ag | Peptides and compositions for treatment of joint damage |
JO3564B1 (ar) | 2013-03-08 | 2020-07-05 | Novartis Ag | ببتيدات وتركيبات لعلاج ضرر المفاصل |
CN104062432B (zh) * | 2013-03-22 | 2016-01-20 | 中山大学 | ang2在制备ECTC血管类型肝癌诊断试剂及治疗药物中的应用 |
AU2014259759B2 (en) | 2013-05-01 | 2020-06-18 | Ionis Pharmaceuticals, Inc. | Compositions and methods |
MX2016008462A (es) | 2013-12-24 | 2016-10-12 | Ionis Pharmaceuticals Inc | Modulacion de la expresion similar a la angiopoyetina tipo 3. |
BR122020024443B1 (pt) | 2014-05-01 | 2022-02-22 | Ionis Pharmaceuticals, Inc | Composto e composição farmacêutica para modulação da expressão de angptl3 |
CN105021827B (zh) * | 2015-07-17 | 2016-09-28 | 北京大学第一医院 | 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用 |
MX2018005277A (es) | 2015-11-06 | 2018-08-01 | Ionis Pharmaceuticals Inc | Modular la expresion de apolipoproteina (a). |
KR102487839B1 (ko) * | 2016-02-04 | 2023-01-12 | 리제너론 파마슈티칼스 인코포레이티드 | 조작된 angptl8 유전자를 갖는 비인간 동물 |
CN117701562A (zh) * | 2017-09-14 | 2024-03-15 | 箭头药业股份有限公司 | 用于抑制血管生成素-样3(ANGPTL3)的表达的RNAi剂和组合物以及使用方法 |
AR116566A1 (es) | 2018-10-03 | 2021-05-19 | Novartis Ag | Administración sostenida de polipéptidos similares a la angiopoyetina 3 |
WO2020099482A2 (en) * | 2018-11-13 | 2020-05-22 | Lipigon Pharmaceuticals Ab | Angptl 3 oligonucleotides influencing the regulation of the fatty acid metabolism |
TWI747098B (zh) * | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
US20220380425A1 (en) * | 2019-07-04 | 2022-12-01 | Cadila Healthcare Limited | Angptl3 based vaccine for the treatment of liver disease |
CN111122872B (zh) * | 2019-11-20 | 2023-01-20 | 中山大学附属第一医院 | 血管生成素样蛋白7在心力衰竭预后评估中的应用 |
CN110938144B (zh) * | 2019-11-27 | 2022-07-26 | 复旦大学附属儿科医院 | 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途 |
WO2022187353A1 (en) * | 2021-03-05 | 2022-09-09 | Anji Pharmaceuticals Inc. | Methods and compositions for treating sepsis |
CN114934021B (zh) * | 2022-04-21 | 2023-08-08 | 复旦大学附属儿科医院 | 一种Angptl3敲除的鼠永生化足细胞系及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596850B1 (en) * | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
EP0917878A4 (en) | 1997-02-26 | 2004-05-19 | Toray Industries | REMEDIES FOR HEPATITIS |
US5972338A (en) * | 1997-09-19 | 1999-10-26 | Genentech, Inc. | Tie ligands homologues |
US6030831A (en) * | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
WO1999055869A1 (en) * | 1998-04-27 | 1999-11-04 | Zymogenetics, Inc. | Novel polypeptide growth factors and materials and methods for making them |
CA2332109A1 (en) * | 1998-05-12 | 1999-11-18 | Human Genome Sciences, Inc. | 97 human secreted proteins |
WO1999067382A2 (en) * | 1998-06-24 | 1999-12-29 | Compugen Ltd. | Angiopoietin-like growth factor sequences |
KR100553300B1 (ko) * | 1999-03-08 | 2006-02-20 | 제넨테크, 인크. | 혈관신생 및 심혈관형성의 촉진 또는 억제 방법 |
CN1615440A (zh) | 2001-11-16 | 2005-05-11 | 杰南技术公司 | 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法 |
-
2002
- 2002-11-13 CN CNA028271920A patent/CN1615440A/zh active Pending
- 2002-11-13 KR KR1020047007410A patent/KR101012904B1/ko active IP Right Grant
- 2002-11-13 ES ES02782310T patent/ES2429034T3/es not_active Expired - Lifetime
- 2002-11-13 NZ NZ532852A patent/NZ532852A/en not_active IP Right Cessation
- 2002-11-13 MX MXPA04004609A patent/MXPA04004609A/es active IP Right Grant
- 2002-11-13 CA CA2464542A patent/CA2464542C/en not_active Expired - Fee Related
- 2002-11-13 CN CN2010102426068A patent/CN101905024A/zh active Pending
- 2002-11-13 AU AU2002348286A patent/AU2002348286B2/en not_active Ceased
- 2002-11-13 WO PCT/US2002/036865 patent/WO2003044172A2/en active Application Filing
- 2002-11-13 EP EP02782310.3A patent/EP1451578B1/en not_active Expired - Lifetime
- 2002-11-13 JP JP2003545797A patent/JP5105696B2/ja not_active Expired - Fee Related
- 2002-11-13 IL IL16154202A patent/IL161542A0/xx not_active IP Right Cessation
- 2002-11-13 KR KR1020107004734A patent/KR20100029861A/ko not_active Application Discontinuation
- 2002-11-15 US US10/298,461 patent/US7267819B2/en not_active Expired - Lifetime
-
2004
- 2004-04-22 ZA ZA2004/03070A patent/ZA200403070B/en unknown
- 2004-06-09 NO NO20042410A patent/NO336021B1/no not_active IP Right Cessation
-
2006
- 2006-09-29 US US11/537,567 patent/US20070134250A1/en not_active Abandoned
-
2008
- 2008-05-28 US US12/128,545 patent/US8541376B2/en active Active
-
2009
- 2009-11-13 JP JP2009259497A patent/JP2010100624A/ja active Pending
-
2010
- 2010-02-11 IL IL203894A patent/IL203894A/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005521643A5 (ja) | ||
JP2010100624A5 (ja) | ||
CN107667115B (zh) | 针对埃博拉病毒糖蛋白的人抗体 | |
US10167333B2 (en) | Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen | |
JP2012504602A5 (ja) | ||
JP2022031635A5 (ja) | ||
JP4294596B2 (ja) | 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法 | |
JP2022191301A5 (ja) | ||
JP2017113019A5 (ja) | ||
JP2009532378A5 (ja) | ||
US20080241162A1 (en) | Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity | |
JP2015523962A5 (ja) | ||
JP2009532336A5 (ja) | ||
JP2007511593A5 (ja) | ||
JP2012500020A5 (ja) | ||
JP2005510246A5 (ja) | ||
RU2000105905A (ru) | Способ лечения острого повреждения легких и способ лечения фиброза, моноклональное антитело, гибридома атсс нв12382 | |
JP2016513682A5 (ja) | ||
JP2007504812A5 (ja) | ||
JP2017537084A5 (ja) | ||
JP2008545381A5 (ja) | ||
RU2017136634A (ru) | Моноклональные антитела против клаудина 1 для профилактики и лечения гепатоцеллюлярной карциномы | |
JP2018518940A5 (ja) | ||
JP2018519804A5 (ja) | ||
JP2005520523A5 (ja) |